Harith Rajagopalan
@Harithr
Followers
1K
Following
881
Media
29
Statuses
2K
Passionate about breaking the pattern of metabolic disease. Co-Founder and CEO, @FractylHealth @BrighamWomens Med/CVMed | @JohnsHopkins MD PhD | @Stanford Chem
Boston
Joined March 2010
Today, we announced an important milestone for Fractyl Health and the future of obesity care. For the first time, randomized, blinded clinical data from the REMAIN-1 Midpoint Cohort demonstrate that Revita® may prevent weight regain after GLP-1 discontinuation at 3 months. In
ir.fractyl.com
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10%...
2
2
12
Largest life science M&A of the week - Penumbra acquired by BSC for $15B after FY revenue of $1.4B. This large deal should help recycle capital for high growth device stories; and may have gone unnoticed by many tx investors… 🤔 where should one look for potentially high
Boston Scientific to buy Penumbra for $374/share (EV ~$14.5B), ~73% cash. $PEN guides FY25 revenue ~$1.4B (+17% to 18%) and 4Q growth ~21% to 22%. $BSX expects $0.06 to $0.08 adj EPS dilution year 1; near neutral year 2.
6
3
20
The headline speaks for itself - for all those who think discontinuation is an “access” issue versus a “health” definition, please note Oprah tried to stop her GLP-1 $GUTS https://t.co/vv7Tlq5Otc
dailymail.co.uk
OprahWinfrey regained a stone-and-a-half when she stopped taking weight loss medication last year.
3
2
17
Remain-1 midpoint data anticipated later in January $GUTS https://t.co/MTREp4V1ju
futurism.com
People who stop taking GLP-1 drugs like Ozempic are finding that their hunger comes back -- with a vengeance.
1
0
34
Roughly 85% of people who start a GLP-1 stop it within 2 years. Weight and cardiovascular benefit are lost when they do. Raises an obvious question: are phase 3 drug studies in obesity asking the most important and relevant question, or are they a scientific exercise with
2
1
22
Holy crap.
We salute you, the lone patient (out of 20K to start!) who managed to stay on treatment for the full 30 months of the semaglutide/tirzepatide STEER study - without any gaps greater than 30 days! 1 tirzepatide patient managed it. No semaglutide patients made it even as far as 27
1
0
8
Hi @statnews and @cooney_liz! As you know, we will have randomized data later this month on #Revita for post-GLP-1 weight maintenance and pivotal data later this year on this exact topic. Post-GLP metabolic rebound is the biggest problem in obesity, and we need better solutions.
Why the weight, and heart risks, return after stopping GLP-1 drugs.
2
1
14
As we close out 2025, I am struck by how far we have come and how much opportunity lies ahead. This year, we advanced our clinical programs, deepened our science, and strengthened the foundation for what could become a fundamentally new chapter in obesity and type 2 diabetes
2
1
17
Chatted with @chrsdurham on his #Downsized podcast about more options for people with #obesity and #T2D:
0
0
4
Every credible study I’ve seen has shown < 50% adherence at 1 year to sema or tzp
Dr. Kristina Lewis of @WakeForest shares the stark contrast between what's happening in clinical trials and clinical practice with respect to continuous use of #obesity #medication 👉 Why are rates lower in clinical practice? Access, cost, coverage, side effects,
3
0
9
Dr. Kristina Lewis of @WakeForest shares the stark contrast between what's happening in clinical trials and clinical practice with respect to continuous use of #obesity #medication 👉 Why are rates lower in clinical practice? Access, cost, coverage, side effects,
2
6
13
Today we shared new 6-month results from the REVEAL-1 Cohort, and the data speak to what we believe is possible for the future of metabolic health. After stopping GLP-1 therapy, participants maintained their weight for six months following a single Revita® procedure. They also
8
8
76
These preclinical results expand the potential of our Rejuva® platform from T2D into obesity research. Our goal: explore whether gene therapy can one day enable durable metabolic control without chronic dosing. RJVA-002 adds momentum as RJVA-001 advances toward first-in-human
ir.fractyl.com
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the...
1
1
7
RJVA-002 expresses GIP + GLP-1 from an engineered insulin promoter to enable beta-cell–specific, nutrient-responsive expression. In preclinical studies: • Single dose → ~30% weight loss at 5 weeks • No adverse effects observed in treated animals These data support continued
1
1
5
A single administration of RJVA-002, a dual GIP/GLP-1 gene therapy candidate, produced ~30% weight loss in a translational obesity model over 5 weeks. Weight loss not yet plateaued. $GUTS 🧬
2
1
15
One thing I respect so much about Dave is that his experience as a patient reflects a key nuance that most market analysts do not understand: appreciating that there are now better drugs to treat the disease while also wishing he didn't have to depend on them. The experience of
The Weekly Dose Podcast $GUTS $LLY
1
1
6
Look forward to speaking with you next week!
$lly $nvo $guts The Revita program from @FractylHealth is extremely promising. Patient who stopped Tirzepatide and got the procedure kept losing, those who stopped and didn’t get it gained 10% back! More data coming in 2026!
0
2
3